Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma.
Adolescent
Adult
Asthma
/ drug therapy
Autoimmune Diseases
/ complications
Brain Neoplasms
/ epidemiology
Case-Control Studies
Child
Child, Preschool
Female
Glioma
/ epidemiology
Humans
Immunosuppressive Agents
/ adverse effects
Infant
Infant, Newborn
Inflammatory Bowel Diseases
/ drug therapy
Logistic Models
Longitudinal Studies
Male
Middle Aged
Odds Ratio
Risk Factors
Survival Analysis
United Kingdom
/ epidemiology
Young Adult
autoimmune diseases
glioma
immunosuppressive therapies
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
07
08
2019
revised:
07
11
2019
accepted:
24
11
2019
pubmed:
11
12
2019
medline:
27
4
2021
entrez:
11
12
2019
Statut:
ppublish
Résumé
Effectors from the immune system can modulate the course and possibly the early development of gliomas. We, therefore, hypothesized that autoimmune diseases associated with increased immune-surveillance may also modulate the risk of human glioma. To test this hypothesis, we used data from the well-validated Clinical Practice Research Datalink (CPRD) GOLD from the UK to analyze the association of immune-related disorders or use of immunosuppressive drugs and the risk of glioma. We identified 3112 incident glioma cases diagnosed between 1995 and 2017. We randomly selected up to 10 controls, matching them to glioma cases on age, sex, index date, general practice, and number of years of active history in the database prior to the index date. We performed conditional logistic regression analyses to estimate Odds Ratios (ORs) of glioma among those exposed to allergies, autoimmune diseases, and immunosuppressive drugs. Overall, we found no materially altered association between a history of any autoimmune disease (OR 0.98, 95% CI 0.86-1.11), allergy (OR 0.97, 95% CI 0.89-1.05), or use of immunosuppressive drugs and the risk of glioma. However, subgroup analyses among younger patients found a statistically significant increased risk of glioma in patients with a history of inflammatory bowel disease (IBD) (OR 2.59, 95% CI 1.31-5.12). There was also an inverse association between asthma and risk of glioma in patients with longer survival (OR 0.73, 95% CI 0.58-0.91) and between long-term duration diabetes and risk of glioma (OR 0.71, 95% CI 0.53-0.96).
Identifiants
pubmed: 31821741
doi: 10.1002/cam4.2767
pmc: PMC6997055
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1263-1275Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Neuron. 2018 Feb 21;97(4):742-768
pubmed: 29470968
J Neurooncol. 2016 Apr;127(2):321-8
pubmed: 26721242
Drugs. 2007;67(8):1167-98
pubmed: 17521218
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Science. 2011 Jan 21;331(6015):337-41
pubmed: 21205640
Cancer Res. 2004 Nov 15;64(22):8468-73
pubmed: 15548720
Br J Cancer. 2014 Apr 2;110(7):1825-33
pubmed: 24595001
Cancer Res. 2009 Nov 1;69(21):8349-55
pubmed: 19808953
Aliment Pharmacol Ther. 2000 Nov;14(11):1443-9
pubmed: 11069315
Nature. 2017 Nov 30;551(7682):585-589
pubmed: 29143823
Cell Host Microbe. 2013 Aug 14;14(2):195-206
pubmed: 23954158
Br J Cancer. 2005 Jun 6;92(11):2070-5
pubmed: 15886700
J Natl Cancer Inst. 2015 Jun 01;107(8):
pubmed: 26032724
Int J Cancer. 2014 Nov 15;135(10):2397-403
pubmed: 24692097
Oncotarget. 2016 Jan 26;7(4):4483-9
pubmed: 26683358
J Intern Med. 2015 Oct;278(4):369-95
pubmed: 26212387
Br J Cancer. 2008 Jul 8;99(1):185-90
pubmed: 18560401
Lancet. 2007 Jul 7;370(9581):59-67
pubmed: 17617273
Am J Cancer Res. 2015 Feb 15;5(3):945-55
pubmed: 26045979
Genome Res. 2012 Feb;22(2):299-306
pubmed: 22009989
Nat Commun. 2016 Jun 28;7:12015
pubmed: 27352007
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4615-22
pubmed: 20660719
Ann Oncol. 2017 Jul 1;28(7):1457-1472
pubmed: 28863449
Neuro Oncol. 2006 Jul;8(3):234-43
pubmed: 16723631
Int J Cancer. 2012 Mar 1;130(5):1160-7
pubmed: 21455988
Allergy. 2011 Nov;66(11):1434-41
pubmed: 21726235
Neuro Oncol. 2013 Sep;15(9):1142-50
pubmed: 23757294
World J Gastroenterol. 2008 Jan 21;14(3):401-7
pubmed: 18200662
Mol Psychiatry. 2013 Jun;18(6):666-73
pubmed: 22688187
Int J Cancer. 2003 Sep 1;106(3):423-8
pubmed: 12845684
Neuro Oncol. 2015 Nov;17 Suppl 7:vii9-vii14
pubmed: 26516226
Brain. 2012 Apr;135(Pt 4):1042-54
pubmed: 22418738
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Clin Exp Immunol. 2003 Oct;134(1):120-6
pubmed: 12974764
Eur J Epidemiol. 2016 Sep;31(9):947-52
pubmed: 27041698
J Clin Oncol. 2009 Dec 10;27(35):5874-80
pubmed: 19901110
Physiol Behav. 2006 Oct 30;89(3):350-7
pubmed: 16887154
Tumour Biol. 2014 Apr;35(4):3875-80
pubmed: 24347487
Cancer Causes Control. 2013 Oct;24(10):1885-91
pubmed: 23903690
J Public Health (Oxf). 2012 Aug;34(3):390-6
pubmed: 22375070
J Clin Invest. 2009 Jan;119(1):182-92
pubmed: 19104149
J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50
pubmed: 17925535
Int J Cancer. 2011 Feb 1;128(3):635-43
pubmed: 20473855
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Nat Neurosci. 2015 Jul;18(7):965-77
pubmed: 26030851
Br J Gen Pract. 2010 Mar;60(572):e128-36
pubmed: 20202356
Cell. 2016 Dec 1;167(6):1469-1480.e12
pubmed: 27912057
Int J Cancer. 2002 May 10;99(2):252-9
pubmed: 11979441
Cancer Med. 2020 Feb;9(3):1263-1275
pubmed: 31821741
Neuro Oncol. 2016 Mar;18(3):340-9
pubmed: 26093337
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):47-54
pubmed: 24220915
Nature. 2015 Jul 16;523(7560):337-41
pubmed: 26030524
Nat Rev Immunol. 2017 Mar;17(3):179-194
pubmed: 28138136
Am J Epidemiol. 2007 Oct 15;166(8):941-50
pubmed: 17646205
Eur J Epidemiol. 2009;24(8):433-40
pubmed: 19484497
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):643-50
pubmed: 15767344
Int J Cancer. 1999 Jul 19;82(2):155-60
pubmed: 10389745
Cancer Cell. 2012 Apr 17;21(4):504-16
pubmed: 22516259
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
J Natl Cancer Inst. 2012 Aug 22;104(16):1251-9
pubmed: 22855780
Nat Rev Cancer. 2013 Nov;13(11):800-12
pubmed: 24132111
Genome Res. 2012 Feb;22(2):292-8
pubmed: 22009990
Epidemiol Rev. 1995;17(2):382-414
pubmed: 8654518
Nature. 2013 Jul 4;499(7456):97-101
pubmed: 23803760
Int J Cancer. 2006 Nov 1;119(9):2165-72
pubmed: 16823851
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Sci Rep. 2017 May 3;7(1):1436
pubmed: 28469238
J Natl Cancer Inst. 2011 Nov 2;103(21):1588-95
pubmed: 22010181
Nat Med. 2009 Sep;15(9):1016-22
pubmed: 19701202
Nature. 2009 Nov 5;462(7269):94-8
pubmed: 19829296
Eur J Neurol. 2011 Mar;18(3):387-95
pubmed: 20722711
J Neurooncol. 2018 Jun;138(2):271-281
pubmed: 29500663
Immunol Rev. 2014 May;259(1):231-44
pubmed: 24712469